Fig. 4: Retroviral/lentiviral engraftment kinetics in patient NYSCT-03.
From: Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny
A Peripheral TCR+ expansion and contraction over time in vivo. B Vector copy number (VCN) kinetics in peripheral circulation. While there was a predominance of retrovirus (RV)-derived product early, there was predominantly lentiviral (LV)-derived product coinciding with the day +25 [18 F]-FHBG PET (C). There was no data beyond day +43, as the patient had passed away, and there was insufficient sample at day +53 for analysis. Data in 4B represent two experimental replicates, ± SD.
